The standard of benefit of Ninlaro (Ixazomib Citrate), combination therapy for multiple myeloma and Lutathera (Lutetium Oxodotreotide) for neuroendocrine cancer will be established.

The HIRA announced that it is proceeding with the amendment of the announcement according to drugs prescribed and administered to cancer patients and will receive comments by the 23rd. It will be applied from the 1st of next month.

Ninlaro is a drug approved for combination therapy with Lenalidomide and Dexamethasone in the treatment of patients with multiple myeloma who have previously received more than one treatment.

According to the textbook review, Ninlaro is mentioned as an oral drug in t